GSK vs. SKX
GSK (GlaxoSmithKline plc) and SKX (Skechers U.S.A., Inc.) are both stocks. GSK operates in Drug Manufacturers - General (Healthcare), while SKX operates in Footwear & Accessories (Consumer Cyclical). At a 0.18 correlation, their price movements are largely independent.
Performance
GSK vs. SKX - Performance Comparison
Loading charts...
Returns By Period
GSK
- 1D
- 0.34%
- 1M
- 6.78%
- YTD
- 9.89%
- 6M
- 10.40%
- 1Y
- 34.50%
- 3Y*
- 19.84%
- 5Y*
- 5.34%
- 10Y*
- 5.35%
SKX
- 1D
- —
- 1M
- —
- YTD
- —
- 6M
- —
- 1Y
- —
- 3Y*
- —
- 5Y*
- —
- 10Y*
- —
GSK vs. SKX - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
GSK GlaxoSmithKline plc | 9.89% | 51.23% | -5.14% | 9.71% | -33.41% | 26.74% | -17.72% | 29.24% | 13.79% | -2.97% |
SKX Skechers U.S.A., Inc. | 0.00% | -6.11% | 7.86% | 48.61% | -3.34% | 20.76% | -16.79% | 88.69% | -39.51% | 53.95% |
Correlation
The correlation between GSK and SKX is -0.03, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | -0.03 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.12 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.16 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.14 |
Correlation (All Time) Calculated using the full available price history since Jun 9, 1999 | 0.18 |
The correlation between GSK and SKX shifts across timeframes, from -0.03 (1 year) to 0.18 (all time), reflecting how their relationship changes across market environments.
Fundamentals
GSK:
$108.04B
SKX:
$9.55B
GSK:
£2.85
SKX:
$4.40
GSK:
13.90
SKX:
14.35
GSK:
0.93
SKX:
0.09
GSK:
2.47
SKX:
1.01
GSK:
3.42
SKX:
2.00
GSK:
£32.78B
SKX:
$9.41B
GSK:
£23.87B
SKX:
$4.96B
GSK:
£11.30B
SKX:
$1.07B
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
GSK vs. SKX — Risk / Return Rank
GSK
SKX
Risk / return metrics aren't available yet — we need at least 12 months of trading data to calculate them.
GSK vs. SKX - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for GlaxoSmithKline plc (GSK) and Skechers U.S.A., Inc. (SKX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| GSK | SKX | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | — | — | |
| Sortino ratioReturn per unit of downside risk | — | — | |
| Omega ratioGain probability vs. loss probability | 1.20 | — | — |
| Calmar ratioReturn relative to maximum drawdown | 1.58 | — | — |
| Martin ratioReturn relative to average drawdown | 3.92 | — | — |
Loading charts...
Drawdowns
GSK vs. SKX - Drawdown Comparison
Loading charts...
Drawdown Indicators
| GSK | SKX | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -55.70% | — | — |
Max Drawdown (1Y)Largest decline over 1 year | -18.63% | — | — |
Max Drawdown (3Y)Largest decline over 3 years | -28.46% | — | — |
Max Drawdown (5Y)Largest decline over 5 years | -50.10% | — | — |
Max Drawdown (10Y)Largest decline over 10 years | -50.10% | — | — |
Current DrawdownCurrent decline from peak | -11.92% | — | — |
Average DrawdownAverage peak-to-trough decline | -18.87% | — | — |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 8.28% | — | — |
Volatility
GSK vs. SKX - Volatility Comparison
Loading charts...
Volatility by Period
| GSK | SKX | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 6.81% | — | — |
Volatility (6M)Calculated over the trailing 6-month period | 18.49% | — | — |
Volatility (1Y)Calculated over the trailing 1-year period | 27.06% | — | — |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 25.08% | — | — |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 22.89% | — | — |
Dividends
GSK vs. SKX - Dividend Comparison
GSK's dividend yield for the trailing twelve months is around 3.26%, while SKX has not paid dividends to shareholders.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
GSK GlaxoSmithKline plc | 3.26% | 3.42% | 4.60% | 3.75% | 5.47% | 4.99% | 5.59% | 4.35% | 5.65% | 5.83% | 6.86% | 5.93% |
SKX Skechers U.S.A., Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Financials
GSK vs. SKX - Financials Comparison
This section allows you to compare key financial metrics between GlaxoSmithKline plc and Skechers U.S.A., Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
GSK vs. SKX - Profitability Comparison
GSK - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, GlaxoSmithKline plc reported a gross profit of 5.75B and revenue of 7.63B. Therefore, the gross margin over that period was 75.4%.
SKX - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Skechers U.S.A., Inc. reported a gross profit of 1.30B and revenue of 2.44B. Therefore, the gross margin over that period was 53.3%.
GSK - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, GlaxoSmithKline plc reported an operating income of 2.29B and revenue of 7.63B, resulting in an operating margin of 30.1%.
SKX - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Skechers U.S.A., Inc. reported an operating income of 173.08M and revenue of 2.44B, resulting in an operating margin of 7.1%.
GSK - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, GlaxoSmithKline plc reported a net income of 1.74B and revenue of 7.63B, resulting in a net margin of 22.8%.
SKX - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Skechers U.S.A., Inc. reported a net income of 170.50M and revenue of 2.44B, resulting in a net margin of 7.0%.
Frequently Asked Questions
GSK and SKX have a correlation of -0.03, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
Find the right allocation for GSK and SKX
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer